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Regional Variation of Mortality in Heart Failure With Reduced and
Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF
Registry
Michael R. MacDonald, MB ChB, BSc (Hons); Wan Ting Tay, MAppStat; Tiew-Hwa Katherine Teng, MPH, PhD; Inder Anand, MD, PhD;
Lieng Hsi Ling, MBBS, MD; Jonathan Yap, MBBS, MPH; Jasper Tromp, MD, PhD; Gurpreet S. Wander, MD, DM; Ajay Naik, MD, DM;
Tachapong Ngarmukos, MD; Bambang B. Siswanto, MD, PhD; Chung-Lieh Hung, MD; ASIAN-HF investigators;* A. Mark Richards, MD, PhD;
Carolyn S. P. Lam, MBBS, PhD
Background-—Data comparing outcomes in heart failure (HF) across Asia are limited. We examined regional variation in mortality
among patients with HF enrolled in the ASIAN-HF (Asian Sudden Cardiac Death in Heart Failure) registry with separate analyses for
those with reduced ejection fraction (EF; <40%) versus preserved EF (≥50%).
Methods and Results-—The ASIAN-HF registry is a prospective longitudinal study. Participants with symptomatic HF were
recruited from 46 secondary care centers in 3 Asian regions: South Asia (India), Southeast Asia (Thailand, Malaysia, Philippines,
Indonesia, Singapore), and Northeast Asia (South Korea, Japan, Taiwan, Hong Kong, China). Overall, 6480 patients aged >18 years
with symptomatic HF were recruited (mean age: 61.613.3 years; 27% women; 81% with HF and reduced rEF). The primary
outcome was 1-year all-cause mortality. Striking regional variations in baseline characteristics and outcomes were observed.
Regardless of HF type, Southeast Asians had the highest burden of comorbidities, particularly diabetes mellitus and chronic kidney
disease, despite being younger than Northeast Asian participants. One-year, crude, all-cause mortality for the whole population was
9.6%, higher in patients with HF and reduced EF (10.6%) than in those with HF and preserved EF (5.4%). One-year, all-cause
mortality was significantly higher in Southeast Asian patients (13.0%), compared with South Asian (7.5%) and Northeast Asian
patients (7.4%; P<0.001). Well-known predictors of death accounted for only 44.2% of the variation in risk of mortality.
Conclusions-—This first multinational prospective study shows that the outcomes in Asian patients with both HF and reduced or
preserved EF are poor overall and worst in Southeast Asian patients. Region-specific risk factors and gaps in guideline-directed
therapy should be addressed to potentially improve outcomes.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identifier: NCT01633398. ( J Am Heart Assoc. 2020;9:
e012199. DOI: 10.1161/JAHA.119.012199.)
Key Words: epidemiology • heart failure • mortality
H eart failure (HF) is a rapidly growing, global public healthproblem that imposes a severe burden of morbidity and
mortality.1 Worldwide, >38 million people have HF,2 at an
estimated cost of US$100 billion in 2012.3 With explosive
population growth in the past century, Asia is currently home to
4.4 billion people (60% of the world’s population), and its
population is projected to reach 5.2 billion by 2050. Exponen-
tial population growth, urbanization, sedentary lifestyle, and an
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aging population together with increasing rates of obesity,
hypertension, and diabetes mellitus, all of which predispose to
HF, have contributed to a “tsunami” of cardiovascular disease,
including HF, in Asia. Asia is highly heterogeneous, with
countries at different stages of economic development.
Population-based data suggest that socioeconomically
deprived persons are likely to develop HF at an earlier age
than affluent individuals.4 Limited data from Southeast Asian
countries also suggest a higher prevalence of HF compared
with other Asian countries.5 This is of increasing concern,
especially as the burden of HF is predicted to be highest in the
poorest countries least equipped to deal with the onslaught.2
Most outcomes data in HF come from European and North
American populations, with scant information from Asia,
restricted to a few individual Asian countries.6,7 In affluent
Western populations, 5-year mortality rates in HF patients
from population-based studies rival those of major cancers at
50–60%.2 The limited data from low- and middle-income
countries suggest their mortality rates may be even higher.6,8
Furthermore, studies have suggested that Asian patients
present with HF on average at least a decade earlier than their
white counterparts, with two thirds presenting with multimor-
bidity.9 The INTER-CHF (International Congestive Heart Fail-
ure) study recently reported marked regional differences in
mortality in patients with HF that persist even after adjust-
ment for known cardiac and noncardiac predictors, suggest-
ing distinctive heterogeneity of the Asian HF phenotype.6
Adding to this complexity, HF subtypes (ie, with reduced
ejection fraction [rEF] or preserved ejection fraction [pEF]) are
heterogeneous syndromes. Epidemiological data on outcomes
in these HF subtypes in Asia are scarce, limited to single-
center or national data.10 The degree of regional variation in
HF outcomes and the underlying reasons for such variations
are uncertain. Research into factors underpinning regional
disparities is necessary to enable targeted action to improve
population-level outcomes. We therefore examined the
regional variation in all-cause and cause-specific mortality
among all patients with HF enrolled in the ASIAN-HF (Asian
Sudden Cardiac Death in Heart Failure) registry with separate




The study data and materials used to conduct the research
cannot be made available to other researchers for purposes of
reproducing the results or replicating the procedure because
of the legal restrictions imposed by multinational jurisdictions.
ASIAN-HF is a prospective observational multinational registry
of Asian patients aged >18 years with symptomatic HF (at
least 1 episode of decompensated HF in the previous
6 months, resulting in a hospital admission or treatment in
an outpatient clinic) recruited from 46 medical centers across
11 Asian regions (China, Hong Kong, India, Indonesia, Japan,
Korea, Malaysia, Philippines, Singapore, Taiwan, and Thai-
land), following informed consent.11 Investigation sites (46 in
total with >220 investigators; Appendix) covered a broad
spectrum of medical, cardiology, and HF specialty units,
admitting patients with acute HF and conducting outpatient
follow-up of patients with chronic HF. Site selection in ASIAN-
HF was based on the size of the country, the geographic
location of the site within the country, the patient population
served, HF patient volume, and availability of expertise in
echocardiography. A mix of private and public hospitals and
tertiary, university, and cardiovascular specialty hospitals in
capital and provincial cities were included. Ethics approvals
conforming to the Declaration of Helsinki were obtained from
the relevant human ethics committees at all sites. Patients
were excluded if they had severe valve disease as the primary
cause of HF, had life-threatening comorbidity with life
expectancy of <1 year, were unable or unwilling to give
consent, or were concurrently participating in a clinical
therapeutic trial. Asian patients were recruited in 2 stages:
those with HF and rEF (HFrEF; EF <40% on baseline
echocardiography) were enrolled between October 1, 2012,
and December 31, 2015, with overlapping recruitment of
those with HF and pEF (HFpEF; EF ≥50% on baseline
echocardiography) between September 9, 2013, and October
31, 2016. Recruitment of patients with HFpEF started later
than the recruitment of patients with HFrEF, for funding
reasons; however, the delay was only 1 year (October 1,
2012, versus September 9, 2013). For the majority of the
recruitment period (until October 6, 2016), there was overlap
in recruitment of both types of HF. We do not anticipate that
there were substantial shifts in epidemiology or treatment of
Clinical Perspective
What Is New?
• This study describes large interregional differences in the
characteristics and outcomes of patients with heart failure
in Asia.
• Heart failure with reduced ejection fraction carries higher
mortality than heart failure with preserved ejection fraction
in Asia, and patients from Southeast Asia have the poorest
outcomes.
What Are the Clinical Implications?
• The results of this study will allow us to target region-
specific risk factors and gaps in guideline-directed therapy
to improve patient outcomes.
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patients with HFrEF or HFpEF during this year that would have
biased regional patterns of multimorbidity, although this
cannot be entirely excluded. All patients included in the
ASIAN-HF registry were required to have a validated clinical
diagnosis of HF (based on symptoms and signs according to
The Framingham Heart Study criteria with decompensation
within 6 months) and left ventricular (LV) EF <40% and ≥50%
for HFrEF and HFpEF, respectively.12 A previous hospitaliza-
tion for HF was defined as any previous hospitalization for HF
during 6 months before inclusion requiring intravenous or oral
diuretic treatment. Patients treated for an episode of decom-
pensation in an outpatient clinic were generally treated with
additional or high dosages of oral diuretics for short periods,
failing which intravenous diuretics would be administered,
usually in a hospital setting. Criteria for recruitment of
patients were standardized across sites. Patients with HFpEF
and a previously recorded LVEF <50% were excluded. In
addition, 99.5% of HFpEF patients had structural or functional
abnormalities meeting the 2016 European Society of Cardi-
ology criteria for diastolic dysfunction (E/e’ ≥13, E’ medial/
lateral <9 ms, left atrial enlargement or LV hypertrophy.1,13
The collection and processing of echocardiographic data
have been reported previously.11 Echocardiography was
performed at each center according to internationally
accepted guidelines.14 Left atrial size, LV diastolic function,
stroke volume, and cardiac output were documented in
addition to LVEF and LV dimensions. The Cardiovascular
Imaging Laboratory of the National University Health System,
Singapore, provided oversight and imaging protocol guidelines
and quality assurance of the echocardiograms. Echocardio-
graphic measurements were performed at the site level with
standardized protocols provided by the echocardiography
laboratory in Singapore.
Demographics (including socioeconomic status), clinical
signs and symptoms, functional status, date of HF diagnosis,
duration of HF, prior cardiovascular procedures or investiga-
tions, clinical and lifestyle risk factors, medical history,
comorbidities, quality of life, and blood chemistry were
documented at recruitment. Standard 12-lead ECG and
transthoracic echocardiography were also recorded at base-
line. Coronary artery disease was defined as the angiograph-
ically documented presence of significant coronary obstruction,
history of myocardial infarction, or prior revascularization.
Hypertension was defined as any past or current history of
hypertension, and diabetes mellitus was defined as having a
prior diagnosis of diabetes mellitus. Estimated glomerular
filtration rate was calculated using the MDRD (Modification of
Diet in Renal Disease) study equation, and chronic kidney
disease (CKD) was defined as estimated glomerular filtration
rate<60 mL/min per 1.73 m2. Atrial fibrillation (AF), peripheral
arterial vascular disease, previous stroke, and chronic obstruc-
tive pulmonary disease were identified by medical history.
Geographic regions were defined according to United
Nations classification as follows: Northeast Asia included
South Korea, Japan, Taiwan, Hong Kong, and China; South
Asia included India; and Southeast Asia included Thailand,
Malaysia, Philippines, Indonesia, and Singapore. National
income level as defined by the World Bank was used to
categorize countries as high, middle, and low income.9
All data were captured prospectively in an electronic
database, with registry operations and data management
handled by Quintiles Outcomes as the contract research
organization appointed by the academic executive committee.
Outcomes
The primary outcome of interest was all-cause mortality at
1 year. In all, 5875 (90.7%) patients had outcome data
available, whereas 605 (9.3%) patients were lost to follow-up.
The cause of death was adjudicated by an independent
committee, using the US Food and Drug Administrations
standardized event definitions.15 Twomembers of the end point
committee independently reviewed the death data collected
from the case report forms; the third member reviewed cases in
which adjudicated causes of death were discordant between
the first 2 members. After the third review, if there was still
discordance, the events were adjudicated at a meeting of the
end point committee. As such, ascertainment of mortality does
not vary between sites.
Causes of death were classified as cardiovascular, noncar-
diovascular, or unknown/presumed cardiovascular in those with
insufficient information on cause of death. Specific mode of
cardiovascular death was further classified as sudden death,HF
death, acute myocardial infarction, stroke, cardiovascular hem-
orrhage, or procedural or other cardiovascular death.
Statistical Analyses
Standard descriptive statistics were used to describe baseline
characteristics by nation and geographic region for patients
with HFrEF and HFpEF separately. Differences in the baseline
characteristics were assessed with ANOVA and v2 tests for
continuous and categorical factors, respectively. Univariable
and multivariable Cox proportional hazards models were used
to assess factors associated with risk of mortality at 1 year,
with geographical region as the key factor of interest. We tested
for interaction in the univariable models with the specific main
effects by geographical region and HF type on 1-year all-cause
mortality outcomes and presented stratified results only if
interactions were significant. Factors associated with mortality
(P<0.1) in univariable models and/or clinically important
factors (demographics, clinical signs, concomitant comorbidi-
ties, pharmacotherapy, or device therapy) were included
for adjustment of the multivariable models. South Asia was
DOI: 10.1161/JAHA.119.012199 Journal of the American Heart Association 3
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used as the reference region because it had the lowest death
rate and the least heterogeneity. Analyses were then repeated
and stratified by geographical region (in the presence of
significant interaction) to assess differences in the risk factors
for 1-year mortality. The Cox proportional hazards assumption
was confirmed using log-log plots and the Schoenfeld residuals
test. The overall assessment of explained risk and relative
importance of a subset of factors in the Cox proportional
hazardsmodels was calculated using the explained risk statistic
and interpreted similarly to the coefficient of determination R2
in the normal linear model.16 Patients who were lost to follow-
up or had incomplete data on adjusted risk factors were
excluded from survival analysis. All analyses were 2-tailed, and
P<0.05 was considered statistically significant. Analyses were
performed in Stata v14 (StataCorp), and explained risk
statistics were calculated in R software v3.4.1.
Results
Overall, 6480 patients (mean age: 61.613.3 years; 27%
women; 81% HFrEF) were enrolled from 46 centers across 11
Asian regions. All patients had a documented episode of
decompensated HF requiring hospitalization or equivalent
outpatient treatment within the 6 months before enrollment.
In addition, 42% of patients were enrolled as inpatients
recruited after initial treatment of acute symptoms and
following stabilization. Vital status was available for 5851
(90.3%) patients who completed 1 year of follow-up. Table 1
describes the baseline characteristics of the entire cohort by
HF group and geographic region. Detailed baseline charac-
teristics at a country level are listed in the Appendix.
Demographics
Demographics varied considerably by geographical region.
Regardless of ejection fraction, Northeast Asian participants
were the oldest, followed by Southeast then South Asian
participants. Patients with HFrEF were on average 8 years
younger than the patients with HFpEF (Table 1). Among the
patients with HFrEF, older cohorts were more likely to be
female; 25.2% of patients in Northeast Asia were female, in
comparison to 17.7% in Southeast Asia. Approximately half of
the patients with HFpEF were women in all 3 regions. The
Philippines had the youngest cohort (20% female), aged
55.8 years, in stark contrast to the patients from Hong Kong,
who were almost 17 years older (46.8% female) at 72.9 years.
Comorbidity
Prevalence of comorbidities was high throughout Asia, but
marked regional variation was evident. Regardless of HF
group, Southeast Asia had the highest prevalence of diabetes
mellitus, stroke, hypertension, CKD, and coronary artery
disease despite a relatively low mean age. In both HFrEF and
HFpEF, ischemic etiology of HF was twice as common in
Southeast Asia as in Northeast and South Asia. In keeping
with the higher prevalence of comorbidities, Southeast Asian
patients also had the highest body mass index (kg/m2) at
25.7 and 28.2 in patients with HFrEF and HFpEF, respectively.
Between countries, patients from the Philippines had the
highest body mass index at 26.9, and those from Japan had
the lowest at 23.0. Across all regions, HFpEF patients had
higher body mass indexes than those with HFrEF. South
Asians had distinctly lower prevalence of AF (4.2% [versus
22.8% average prevalence in other geographical regions] in
HFrEF and 7.2% [versus 23.6% average prevalence in other
regions] in HFpEF) and chronic obstructive pulmonary
disease.
Pharmacological and Device Therapy
Despite the lack of evidence-based HF therapies for HFpEF
patients, angiotensin-converting enzyme inhibitors (ACEIs),
angiotensin receptor blockers (ARBs), and b-blockers were
usually prescribed in both HFrEF and HFpEF patients
(Table 1). Southeast Asia had the highest rates of ACEI and
ARB use (77.3% and 70.2%, respectively) and b-blocker use
(81.8% and 78.9%, respectively), whereas mineralocorticoid
receptor antagonists were most frequently prescribed in
Northeast Asia for 61.7% and 26.6% of HFrEF and HFpEF
patients, respectively. Marked variation in pharmacological
treatment was observed at the country level—for example,
Indonesia had the lowest usage (61.7%) of b-blockers but the
highest (85.8%) of ACEIs/ARBs; Japan had highest usage of b-
blockers (89.5%) but moderate usage (78.4%) of ACEIs/ARBs.
There was wide variability in device implantation across
countries and regions, with Japan having the highest rate.
Outcomes
One-year outcome data were available for 93% of patients in
South Asia, 86% in Southeast Asia, and 93% in Northeast Asia.
One-year crude all-cause mortality for the whole population
was 9.6%, with a higher mortality rate for patients with HFrEF
than HFpEF (10.6% and 5.4%, respectively; P<0.001). In
almost all countries, participants recruited as inpatients had
almost twice (13.4% versus 6.8%) the 1-year mortality of those
recruited as outpatients. Figures 1 through 3 and Tables 2
and 3 detail 1-year outcomes.
Among patients with HFrEF, Southeast Asia had the
highest crude all-cause mortality at 13.6% compared with
8.9% and 8.3% in Northeast Asia and South Asia, respectively.
The high mortality in Southeast Asia was largely driven by a
DOI: 10.1161/JAHA.119.012199 Journal of the American Heart Association 4
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21.4% mortality rate in Indonesia and 14.3% in the Philippines,
despite these 2 countries having the youngest populations.
Japan, with a relatively elderly population, had the lowest 1-
year mortality rate at 4.4%.
Overall, the most common cause of death among patients
with HFrEF (54%) was known cardiovascular death, with a
further 34% of deaths having a presumed cardiovascular or
unknown cause, whereas 12% of deaths were noncardiovas-
cular. Sudden death and HF death accounted for at least 80%
of cardiovascular deaths. Among patients with HFpEF,
cardiovascular and noncardiovascular deaths accounted for
half and a quarter of deaths, respectively.
Associations With Mortality
Table 4 demonstrates the variables associated with 1-year
mortality in the entire ASIAN-HF cohort. In unadjusted
analyses, multiple variables were associated with death. After
adjustment, clinical and demographic features associated
with death within 1 year included enrollment as an inpatient
(hazard ratio [HR]: 1.49; 95% CI, 1.19–1.86), HFpEF (HR: 0.54;
95% CI, 0.37–0.80), New York Heart Association (NYHA) class
III/IV (HR: 1.99; 95% CI, 1.60–2.47), body mass index (HR:
0.95; 95% CI, 0.93–0.97), systolic blood pressure (HR: 0.90;
95% CI, 0.85–0.95), AF (HR: 1.33; 95% CI, 1.05–1.67), and
CKD (HR: 1.58; 95% CI, 1.27–1.97). Treatment with an ACEI/
ARB and treatment with a b-blocker were both independently
associated with better survival, with HRs of 0.61 (95% CI,
0.50–0.76) and 0.66 (95% CI, 0.52–0.83), respectively.
However, use of mineralocorticoid receptor antagonists was
not associated with outcomes, and use of diuretics was
associated with worse outcomes (HR: 1.96; 95% CI, 1.37–
2.82). There were a number of interactions with regional
status in the univariable models. AF was associated with poor
prognosis in South Asian patients (HR: 2.79; 95% CI, 1.31–
5.94) and Northeast Asian patients (HR: 1.55; 95% CI, 1.07–
2.25) but not in Southeast Asian patients, in whom it was not
significantly associated with mortality. There was also a
significant interaction between enrollment as an inpatient and
region. Inpatient enrollment was associated with higher
mortality than outpatient enrollment in Northeast and South
Asia but not in Southeast Asia. Southeast Asia had almost
double the adjusted risk of mortality of the other 2 regions
(HR: 1.94; 95% CI, 1.42–2.66). The relationship between
geographical region and outcomes was not significantly
affected by HF type (Pinteraction=0.075), such that Southeast
Asia had higher risk of mortality compared with South and
Northeast Asia for both HFrEF and HFpEF.
Table 5 shows the contribution of each demographic,
clinical, medication/device, and regional variable that con-
tributed to the relative amount of the risk of death at 1 year.
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death and consisted of 3.9% demographic, 21.9% clinical,
7.0% medication/device, and 5.8% regional variables. The
relative contributions were similar in HFrEF, comprising 3.8%
demographic, 18.2% clinical, 7.8% medication/device, and
5.3% regional variables. In HFpEF, however, known variables
accounted for 49.0% of the risk of death, mostly contributed
by demographics and region.
Discussion
The ASIAN-HF study is the first multinational prospective
registry to present outcomes data for patients with HF by
regions and HF subtypes across Asia. Crude 1-year all-cause
mortality was 9.6% in the overall cohort. However, we
observed significant regional differences in patient character-
istics, treatment, and mortality. Asian patients with HFrEF had
worse 1-year outcomes than those with HFpEF, despite being
significantly younger. Patients from the lowest income
countries presented at the youngest ages but had the poorest
outcomes. Southeast Asia had the highest rate of comorbidi-
ties, and patients from this region were almost twice as likely
to die during the first year of follow-up in comparison to
patients from South and Northeast Asia. Despite the consid-
erable regional variations in demographics, comorbidity, and
treatment, these measured factors explain less than half of
the interregional variation in mortality, with unmeasured
factors accounting for the bulk of the varying mortality risk.
Notably, region was as or more important than demographics
in predicting mortality in both HFrEF and HFpEF patients.
Few other studies have explored the outcomes of patients
with HF in Asia at national and regional levels.10 The INTER-
CHF study was a prospective HF cohort study conducted in
108 centers worldwide.6 In addition to enrolling patients from
the Middle East, Africa, and South America, INTER-CHF also
enrolled 2660 patients from 4 Asian countries: China, India,
Malaysia, and the Philippines. Unlike ASIAN-HF, INTER-CHF
did not report outcomes in the different HF subtypes. The 1-
year mortality rate in Southeast Asia (Malaysia and Philip-
pines) in INTER-CHF was 15%, which is comparable to the
mortality in our own Southeast Asian cohort (covering 5
countries) at 13%. However, the INTER-CHF mortality rates for
China (7.3%) and India (23.3%) do not accord with our data;
this is attributed to marked differences in patient character-
istics of both studies. In ASIAN-HF, we found almost double























1 year mortality rates
CV Non CV Unknown
Figure 1. One-year mortality and cause of death by region and heart failure group. CV indicates
cardiovascular; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved
ejection fraction.
Figure 2. Kaplan–Meier curves for mortality by region.
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rate in India (7.7%). The mortality variation in China may well
be explained by the differing proportions of patients with
HFrEF and inpatients in each study; in INTER-CHF, 27% of
Chinese patients had HFrEF and 35% were recruited as
inpatients. In contrast, the corresponding proportions of
China’s participants in ASIAN-HF were 98.8% with HFrEF and
91.3% recruited as inpatients. Higher mortality in the INTER-
CHF population from India may be partly explained by a sicker
population, with patients more likely to be enrolled as
inpatients, to have more NYHA III/IV class HF, and to use
fewer ACEIs/ARBs and b-blockers compared with ASIAN-HF
participants.
The SWEDE-HF (Swedish Heart Failure) registry had
enrollment criteria similar to the ASIAN-HF registry, so it is
a useful comparator to represent non-Asian populations.
Crude 1-year mortality rates for patients with EF <40%
(n=23 400) and EF ≥50% (n=9640) were 15% and 17%,
respectively. These rates are higher than those in the ASIAN-
HF cohort but may partly reflect the older age of the Swedish
cohort, with a mean age of 72 years for HFrEF and 77 years


























































































































































































































































































































































































































































































































































































































































































































Figure 3. Kaplan–Meier curves for mortality by heart failure
group. A, Heart failure with reduced ejection fraction (HFrEF). B,
Heart failure with preserved ejection fraction (HFpEF).
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68 years, respectively, in ASIAN-HF participants. Other
notable differences in the populations were a far higher
proportion of patients with AF in the Swedish cohort, at 51%
in those with HFrEF and 63% in those with HFpEF. In addition,
the Swedish cohort had a higher proportion of female
participants, with 29% of HFrEF patients and 55% of HFPEF
patients being female.17
We previously described the interregional differences in
clinical and echo characteristics and outcomes of patients
with HFpEF in the ASIAN-HF population. We found that in
patients with HFpEF, Southeast Asian patients had the highest
rate of comorbidities and LV hypertrophy and the poorest
outcomes. We extend this study in a number of ways by (1)
presenting mortality rates for HFrEF and comparing these with
HFpEF, (2) investigating differences in adjudicated causes of
death in patients with HFrEF and HFpEF, and (3) studying
differences in predictors of clinical outcomes between
patients with HFrEF and HFpEF from Asia. A similar pattern
of comorbidity clustering occurs in HFrEF patients, with
particularly high rates of comorbidities and mortality in
Southeast Asia. Mortality rates are almost double in HFrEF
patients despite their being significantly younger.
After multivariable analysis we found that the relationship
between certain key factors and mortality was modified by
regional status. Enrollment as an inpatient was associated
with significantly worse outcomes in Northeast and South
Asia but not in Southeast Asia. This may reflect that inpatients
in Southeast Asia may not be as sick as inpatients in
Northeast and South Asia, or perhaps be due to dispropor-
tionately higher enrollment of inpatients from Singapore and
Malaysia, where there is good tertiary care. Interestingly, in
patients from South Asia, AF was associated with a far greater
risk of death than in other regions. This result is particularly
intriguing, given the markedly lower prevalence of AF in the
South Asian population, and further study is warranted.
At a national level, Indonesia had the highest rate of all-
cause death at 22.6%, with the second highest in Hong Kong
at 19.8%—an interesting finding, given that Indonesia had the
youngest population in the cohort (mean age: 57 years) and
Hong Kong had the oldest (mean age: 79 years). It is notable
that Indonesia also had the highest rates of coronary artery
disease (62%) and smoking (66.4%) and a high prevalence of
CKD but the lowest uptake of implantable cardioverter-
defibrillators and cardiac resynchronization therapy–defibril-
lators and b-blockers. The finding of poor outcomes in young
patients in Asia was reported previously from a subgroup
analysis of the PARADIGM-HF trial that compared patient
characteristics and outcomes among different global geo-
graphic regions, including 1487 patients with HFrEF from the
Asia Pacific region.18 Patients in the Asia Pacific region were
on average 10.5 years younger than their western European
counterparts at enrollment and had one of the highest rates
of all-cause mortality and cardiovascular death globally,
before and after adjustment for clinical characteristics.
Poorer outcomes in younger Southeast Asian populations
may reflect later presentation and more advanced disease
but also the lower life expectancy seen in lower income
countries such as Indonesia and the Philippines, which have
vast geographic spread and less developed healthcare
infrastructure.
We found marked divergence in both drug and device
utilization across Asia. Device utilization in Northeast Asia
was more than 3-fold that seen in Southeast and South Asia,
with particularly high rates of device usage in Japan. The
disparity in device utilization across geographical regions was
recently described in a pan-Asian analysis from ASIAN-HF.19















No. of cardiovascular deaths 64 104 173 61 97 151 3 7 22
Specific cause of cardiovascular death
Sudden death 41 (64.0) 43 (41.3) 49 (28.3) 41 (67.2) 41 (42.3) 47 (31.1) 0 (0.0) 2 (28.6) 2 (9.1)
HF death 18 (28.1) 52 (50.0) 41 (23.7) 17 (27.9) 47 (48.4) 39 (25.8) 1 (33.3) 5 (71.4) 2 (9.1)
AMI death 4 (6.3) 5 (4.8) 14 (8.1) 3 (4.9) 5 (5.2) 11 (7.3) 1 (33.3) 0 (0.0) 3 (13.6)
Stroke death 1 (1.6) 2 (1.9) 7 (4.0) 0 (0.0) 2 (2.1) 6 (4.0) 1 (33.3) 0 (0.0) 1 (4.6)
Cardiovascular hemorrhage death 0 (0) 1 (1.0) 4 (2.3) 0 (0.0) 1 (1.0) 2 (1.3) 0 (0.0) 0 (0.0) 2 (9.1)
Procedure death 0 (0) 1 (1.0) 2 (1.2) 0 (0.0) 1 (1.0) 2 (1.3) 0 (0.0) 0 (0.0) 0 (0.0)
Other cardiovascular death 0 (0) 0 (0) 56 (32.4) 0 (0.0) 0 (0.0) 44 (29.1) 0 (0.0) 0 (0.0) 12 (55.5)
Data are shown as n (%) except as noted. AMI indicates acute myocardial infarction; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced
ejection fraction.
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Table 4. Variables Associated With All-Cause Mortality At 1 Year
Univariable Analysis Multivariable Analysis Interaction With Region
HR (95% CI) P Value HR (95% CI) P Value Pinteraction Northeast Asia South Asia Southeast Asia
Demographic variables
Age, per 10 y 1.13 (1.06–1.21) <0.001 1.07 (0.98–1.18) 0.148 0.002 1.08 (0.93–1.26) 0.94 (0.77–1.15) 1.17 (1.02–1.33)
Female 0.81 (0.67–0.99) 0.038 0.97 (0.74–1.27) 0.834 . . . . . . . . . . . .
Enrolled as inpatient 2.12 (1.79–2.51) <0.001 1.47 (1.17–1.84) 0.001 0.001 1.88 (1.21–2.93) 1.86 (1.11–3.12) 1.20 (0.89–1.62)
HF hospitalization in
past 6 mo
1.87 (1.59–2.21) <0.001 1.47 (1.20–1.80) <0.001 0.062 . . . . . . . . .
Clinical variables
HFpEF 0.51 (0.39–0.67) <0.001 0.55 (0.37–0.83) 0.004 . . . . . . . . . . . .
NYHA class III/IV 2.26 (1.91–2.68) <0.001 1.93 (1.54–2.42) <0.001 . . . . . . . . . . . .
Body mass index, kg/m2 0.94 (0.93–0.96) <0.001 0.95 (0.93–0.97) <0.001 . . . . . . . . . . . .
Heart rate, per 5 bpm 1.02 (1.00–1.05) 0.074 1.02 (0.99–1.05) 0.201 . . . . . . . . . . . .
Systolic BP, per
10 mm Hg
0.89 (0.86–0.93) <0.001 0.91 (0.86–0.97) 0.002 . . . . . . . . . . . .
Diastolic BP, per
10 mm Hg
0.87 (0.81–0.93) <0.001 . . . . . . . . . . . . . . . . . .
Duration of HF, y 1.20 (1.11–1.31) <0.001 1.16 (1.04–1.29) 0.006 . . . . . . . . . . . .
Ischemic etiology
of HF
1.64 (1.38–1.95) <0.001 . . . . . . . . . . . . . . . . . .
Coronary artery
disease
1.53 (1.30–1.81) <0.001 1.14 (0.91–1.42) 0.265 . . . . . . . . . . . .
AF 1.44 (1.19–1.74) <0.001 1.35 (1.06–1.71) 0.013 0.019 1.55 (1.07–2.25) 2.79 (1.31–5.94) 1.15 (0.84–1.57)
Hypertension 1.11 (0.94–1.31) 0.218 . . . . . . . . . . . . . . . . . .
Prior stroke 1.38 (1.03–1.85) 0.029 0.99 (0.70–1.40) 0.975 . . . . . . . . . . . .
PAD 2.28 (1.63–3.20) <0.001 1.41 (0.92–2.17) 0.117 . . . . . . . . . . . .
COPD 1.33 (1.01–1.74) 0.039 0.88 (0.63–1.24) 0.479 . . . . . . . . . . . .
Diabetes mellitus 1.37 (1.16–1.61) <0.001 1.06 (0.85–1.31) 0.621 . . . . . . . . . . . .
Renal artery stenosis 2.34 (1.29–4.26) 0.005 . . . . . . . . . . . . . . . . . .
Cancer 1.12 (0.73–1.73) 0.607 . . . . . . . . . . . . . . . . . .
Smoking, ever 1.33 (1.13–1.57) 0.001 0.99 (0.78–1.25) 0.930 . . . . . . . . . . . .
Alcohol, ever 1.05 (0.87–1.27) 0.596 . . . . . . . . . . . . . . . . . .
CKD 1.97 (1.64–2.37) <0.001 1.57 (1.26–1.97) <0.001 . . . . . . . . . . . .
Left bundle-branch
block
0.96 (0.74–1.25) 0.758 . . . . . . . . . . . . . . . . . .
Medications/device use
ACEI or ARB 0.55 (0.46–0.65) <0.001 0.61 (0.49–0.75) <0.001 . . . . . . . . . . . .
b-Blocker 0.63 (0.52–0.75) <0.001 0.66 (0.52–0.83) <0.001 . . . . . . . . . . . .
Mineralocorticoid
receptor antagonist
0.89 (0.75–1.05) 0.161 0.90 (0.72–1.11) 0.325 . . . . . . . . . . . .
Diuretic 2.01 (1.54–2.64) <0.001 1.87 (1.30–2.69) 0.001 . . . . . . . . . . . .
Digoxin 1.35 (1.13–1.62) 0.001 . . . . . . . . . . . . . . . . . .
ICD/CRT-D 0.92 (0.69–1.22) 0.558 0.75 (0.53–1.08) 0.119 . . . . . . . . . . . .
ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BP, blood pressure; CKD, chronic kidney disease; COPD, chronic
obstructive pulmonary disease; CRT-D, cardiac resynchronization therapy–defibrillator; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HR, hazard ratio; ICD,
implantable cardioverter-defibrillator; NYHA, New York Heart Association; PAD, peripheral arterial disease.
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The ASTRONAUT (Aliskiren Trial on Acute Heart Failure
Outcomes) study20 previously reported low rates of guideline-
directed medical therapy and very low rates of implantable
cardioverter-defibrillator utilization in a small group of patients
(n=439) from the Asia Pacific region (India, Singapore, Israel,
Philippines, Turkey, Taiwan). Implantable cardioverter-defibril-
lator usage was 5.7% in Asia Pacific in comparison to 38% in
North America, and patients from the Asia Pacific region had the
highest 1-year all-cause mortality rate at 26.7%, in comparison
to 7.3% in North America. The largest driver of regional
differences in mortality was sudden cardiac death, with a 10.3%
1-year rate of sudden cardiac death in Asia compared with 1.6%
in North America.
The clear interregional differences in mortality seen in
ASIAN-HF were only partly explained by differences in patient
demographics, comorbidities, and treatment. These measured
variables account for less than half of the variation in mortality
risk after multivariable adjustment. The majority of regional
variation in mortality arises from unmeasured factors that likely
include differences in healthcare infrastructure, delayed pre-
sentation to healthcare facilities, access to and delivery of
health care, and the quality of healthcare, as shown by the
poorest countries having the greatest mortality. Other impor-
tant variables such as genetic, cultural, and environmental
factors may also be operative. Consequently, efforts at
unraveling and addressing these unmeasured factors, including
improvements in national and regional healthcare infrastruc-
ture and organization, may have great potential for enhancing
survival outcomes in Asian HF patients. With pharmacological
management and device therapy explaining only 7% of variation
in the risk of mortality in the fully adjusted model in chronic
patients with HF, primary prevention of HF through attention to
its key risk factors or antecedents (eg. coronary artery disease,
hypertension, diabetesmellitus, and CKD) is key to reducing the
burden of HF in Asia.
Limitations
There is a potential bias in site selection (with a clear bias to
reputable, academically inclined centers with expertise in
echocardiography and resources to devote to research
activities) and willingness of patients to participate in a
prospective registry. Priority was given to sites that could
provide high-quality data with as little missing data as
possible. Therefore, the experience of our centers likely
represents the best practice achievable in our multinational
observational registry. Our results may therefore underesti-
mate the true outcome burden of HF across Asia. Underre-
porting bias is also a possibility. To minimize this, every effort
was made to ensure protocol standardization and adherence,
including on-site investigator training, regular monitoring
(both in person and remote), and centralized database
management. Variation in reporting of cause of death across
the different sites precluded the ascertainment of the cause
of death in a significant proportion of cases, with subsequent
substantial percentage variation in the category of death with
unknown cause. However, in the absence of official pan-Asian
population-based data, ASIAN-HF provides the best informa-
tion available on HF to date across a broad swathe of Asia.
Conclusions
These first multinational prospective outcomes data on
patients with HF across 11 Asian regions show that patients
from Southeast Asia (particularly low-income countries with
the youngest patients) had the poorest outcomes regardless
of LVEF. Region-specific risk factors and gaps in guideline-
directed therapy should be addressed, along with exploration
of potential regional differences in healthcare systems,
access to device therapy, and genetic and environmental
factors.
Table 5. Explained Risk Analysis
1-y Mortality
Overall* HFrEF* HFpEF†
Value (%) SE (%) Value (%) SE (%) Value (%) SE (%)
Demographic variables+clinical variables+
medication or device use+region
44.8 2.9 42.7 3.2 49.0 7.9
Only demographic variables 3.9 1.6 3.8 1.7 20.4 9.7
Only clinical variables 21.9 3.2 18.2 3.2 11.5 7.8
Only medications/device use 7.0 2.0 7.8 2.2 . . . . . .
Only region 5.8 1.9 5.3 2.0 21.8 8.8
HFpEF indicates heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
*Adjusted for demographic variables (age, sex, inpatient enrollment), clinical variables (New York Heart Association class, body mass index, heart rate, systolic blood pressure, duration of
heart failure, coronary artery disease, atrial fibrillation, prior stroke, peripheral arterial disease, chronic obstructive pulmonary disease, diabetes mellitus, smoking, chronic kidney disease),
medication or device use (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, b-blocker, mineralocorticoid receptor antagonist, diuretic, implantable cardioverter-
defibrillator/cardiac resynchronization therapy–defibrillator) and regional variables.
†Adjusted for demographic (age, inpatient enrollment), clinical (New York Heart Association class, body mass index, duration of heart failure), and regional variables.
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